OBJECTIVES To review the available systemic treatments for women with recurrent ovarian cancer. METHODS A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer...

OBJECTIVE The objective of this study was to compare hospital costs per treatment cycle (HCTC) for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer (AdvNS-NSCLC) in Chinese patients. METHODS Patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC from 2010 t...

The metal resistant bacterium Cupriavidus metallidurans CH34, challenged with aqueous platinous and platinic chloride, rapidly immobilized platinum. XANES/EXAFS analysis of these reaction systems demonstrated that platinum binding shifted from chloride to carboxyl functional groups within the bacteria. Pt(IV) was more toxic than Pt(II), presumably due to the oxidative stress imparted by the pla...

Ovarian cancer is characterized by an increase in cellular energy metabolism, which is predominantly satisfied by glucose and glutamine. Targeting metabolic pathways is an attractive approach to enhance the therapeutic effectiveness and to potentially overcome drug resistance in ovarian cancer. In platinum-sensitive ovarian cancer cell lines the metabolism of both, glucose and glutamine was ini...

a-Amino Acid Esters, Peptide Esters, Platinum(IV) Complexes, "N NMR Spectra, Pt NMR Spectra The platinum(IV) complexes PtX4L2 (X = Cl, Br; 2 X = oxalate; L = glyOEt, glyglyOEt, gly-cleuOEt; 2 L = metOEt) have been obtained by oxidative addition of halogenes to platinum(II) compounds PtX2L2A high field shift of <3N (—50 ppm) is observed for the coordinated amino acid ligand of various platinum c...

OBJECTIVE Primary platinum-resistant epithelial ovarian cancer (EOC) is an area of unmet medical need. There is limited evidence from small studies that platinum-based combinations can overcome "resistance" in a proportion of patients. We investigated the efficacy and toxicity of platinum-based combination chemotherapy in the platinum-resistant and platinum-refractory setting. METHODS Epirubi...

the development of metal-based therapeutics. Cisplatin is one platinum complex and is widely used in treatments for cancer. Shimizu and Tsuji established a method of preparing colloidal platinum particles, whose average size is 2 nm, by ethanol reduction of H2PtCl6 in the absence of protective agents such as hydrophilic polymers. They used only the chemicals permitted to food additives such as ...

BACKGROUND Ovarian cancer remains an on-going challenge mainly due to the development of drug resistance and also because the cancer is likely to have metastasized at the time of diagnosis. Currently, chemotherapy based on platinum drugs such as cisplatin is the primary treatment for the disease. Copper transporter 1 is involved in the transport of cisplatin into the cell, but is also down-regu...

Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid platinum inefficacy and to exploit platinum sensitivity. TOV-21G d...

Platinum resistance is a critical barrier for clinicians to improve the survival of ovarian cancer. Our study evaluated the correlation between copy number variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the prognosis of ovarian cancer, which might predict platinum resistance in ovarian cancer patients.Array comparative genomic hybridization (CGH) was used to test gene ...